ye7 fun

Two B.C. critical mineral recycling technology companies announced plans today to build a plant in Texas that would produce magnet metals from e-waste. The American company, HyProMag, has completed a feasibility study for the construction of a US$125 million magnet recycling plant in Dallas Fort Worth, Texas. HyProMag has been commercializing a process for recycling magnets -- Hydrogen Processing of Magnet Scrap (HPMS) -- developed by the University of Birmingham Magnetic Materials Group. HyProMag is owned by Maginito Ltd . – subsidiary of two B.C. headquartered companies, CoTec Holdings Corp. (TSX-V:CTH, OTCQB:CTHCF) and Mkango Resources Ltd. (TSX-V:MKA, AIM:MKA). In a feasibility study released today, CoTec revealed plans for a recycling plant in Texas that would produce “permanent magnets” from e-waste – mainly from hard drive discs from computers. Recycling critical minerals, including rare earths and magnet metals, is becoming a security issue for the U.S., Europe and other Western countries and allied nations. “The Chinese have been taking steps recently to restrict various strategic materials,” CoTec CEO Julian Treger told BIV News. “Most recently the Russians have done something on uranium. And it’s just a matter of time before there are further restrictions on rare earths magnets. And they are crucial not only for strategic purposes such as night goggles and ballistic missile guidance systems, but also for drones, robots and super necessary in the hard drives that power AI. So, sooner or later, the ability to generate a domestic recycled supply of these materials is going to be very, very valuable.” The proposed Texas plant would produce 750 metric tonnes annually of recycled neodymium iron boron (NdFeB) – otherwise known as permanent magnets -- over a 40 year operating life, according to the feasibility study. Given the national security concerns over securing domestic supplies of critical minerals and materials, the companies will be looking for grants from the American government to help build the plant Treger said. “We’re also going button down the feedstock supply, and we’re engaging with a number of people in the U.S. industry who can supply us with the waste that we need. And then there are a number of people who want to be customers. All of that needs to be buttoned down before we move to the financing phase. Obviously that will depend on how successful we are in obtaining grants.” CoTec is focused on identifying and acquiring mineral recovery technology. CoTec’s senior management includes former executives and engineers from major mining companies like Rio Tinto and Anglo Pacific Group Plc, and its board of directors includes Bob Harward -- a retired U.S. Navy Vice Admiral and former Deputy Commander of the United States Central Command. “We, as CoTec, have looked at 400 technologies,” Treger said. “We’ve invested in six, so far. We are very picky about things that are really category killers and really move the needle and are disruptive.” “It’s an attempt to invent the 21 st Century responsible commodity extraction business – super green, very low carbon, low cost – and finally deploying the disruptive technologies which are out there (but) which the major mining companies haven’t done so far because of inertia,” Treger said. Making permanent magnets from neodymium, iron and boron is a complex, painstaking process, Treger said. The HyProMag process extracts the NdFeB from spent magnets, rendering them into a powder and then uses a process for reconstituting the magnets in what Teger describes as a “short-looped process.” “We don’t process the individual elements – we just recycle the mix,” Treger said. “It’s a way for the West to basically use its embedded, vast historic supply of magnets in a really strategic way to be much more self-sufficient, which is why it’s obviously of great interest to the U.S. and the Defence sector. “The short-looped process is a short-cut getting these things made and produced, whereas most other recycling opportunities I see are looking to recycle the individual elements of the rare earths, which is very, very difficult thing to do.” Other technologies the company has invested in include copper and iron extraction from copper and iron mine waste. One of the companies CoTec has invested in is Ceibo, which developed a copper recovery technology that Glencore recently announced it will be using at the Lomas Bayas copper mine in Chile. Treger said there is potential for a lot of copper and iron waste recovery in Canada. “We have a major interest in waste,” Treger said. “In Canada alone there are 10,000 closed mines, with waste associated with them, which have enormous liabilities. “We are looking at an iron ore recycling project in Quebec to see how we can scale this and work with the various provinces to minimize their rehabilitation coat and use the historic legacy of all this waste we have hanging around to supply the materials that the west is going to need.” [email protected] twitter.com/nbennett_bivbetfred reviews 。

MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIVNo. 22 Xavier aims to keep its perfect record intact Monday night in Fort Myers, Fla., when it takes on South Carolina in the Fort Myers Tip-Off. The Musketeers (5-0) are coming off an 80-55 victory on Wednesday over Siena, while the Gamecocks (3-2) beat Mercer on Thursday 84-72. Against Mercer, South Carolina sank a season-best 12 3-pointers -- tied for the fourth-most in a single game under third-year coach Lamont Paris. Jamarii Thomas, a senior transfer from Norfolk State, had 19 points and swished 4 of 5 shots from behind the arc. "Thomas got some good, clean looks," Paris said. "It was good to see those guys make their shots. Hopefully it gets those guys going in the right direction." On the season, the Gamecocks are making 7.8 3-pointers per game and shooting 32.5 percent from deep. Senior guard Jacobi Wright makes a team-best 1.8 3-pointers per game and shoots 37.5 percent from behind the arc. At 13.0 ppg, he is second on the team behind Collin Murray-Boyles (15.8). Xavier is allowing eight makes from deep per game and is letting opponents shoot 38.5 percent from behind the arc, which ranks 337th in the country. And despite an undefeated record so far for the Musketeers, third-year coach Sean Miller is worried about his players developing bad habits. "We have a virus that everybody is looking at the stat sheet, trying to get as many points as they possibly can," Miller said after the win over Siena. "They want to win, but they really want to win and score. We need a couple of guys that are willing to rebound, defend, make the extra pass, play at a high level defensively and understand what makes a team great." Marcus Foster did a decent job of doing a little bit of everything for Xavier against Siena, piling up 12 points, five rebounds, five assists and a steal. It was the first double-digit scoring outing for Foster -- a grad transfer from Furman -- in a Xavier uniform. Since 2008, Xavier is 25-11 against teams from the Southeastern Conference, but it hasn't played South Carolina in that stretch. --Field Level Media

Will Riley's 19 points in the 2nd half leads No. 25 Illinois past Maryland Eastern Shore 87-40U.S. president-elect Donald Trump and those in his corner continue to muse about annexing Canada, though Canadian officials have largely sidestepped those comments. In a post on the social media platform X, Eric Trump shared a doctored photo of his father purchasing Canada, Greenland and the Panama Canal on Amazon, with the phrase “We are so back!!!” Since winning the presidential election in November, Trump has repeatedly referred to Canada as the “51st state.” On Trump’s Truth Social platform, he’s also repeatedly referred to Prime Minister Justin Trudeau as the “governor” of Canada. Trump has also threatened 25 per cent tariffs against Canada, which has prompted discussions at both the federal and provincial levels on the best way to deal with the incoming Trump government. Carleton University professor Aaron Ettinger said federal officials have rightly been dismissing the social-media posts and maintained a “focus like a laser beam” on the real and “existential threat” of tariffs. “This strikes me as being profoundly unserious,” said Ettinger, who has studied Canada-U.S. relations during the first Trump presidency. “These are taunts; these are churlish provocations that are not mature, and do not reflect just how serious the coming trade war is,” he said. Ettinger said Trump is likely continually posting about Canada because it plays well to his supporters, without being seen as a real threat of annexation. “We know his moves. He makes fun of, he belittles, he mocks, because he can,” he said. But he said that a vacuum of leadership in Ottawa from embattled Prime Minister Justin Trudeau is spurring “the freelancing of some of the provincial leaders” in response to Trump’s comments. For example, Ontario Premier Doug Ford weighed in on Trump’s postings on Dec. 18, telling media that “we’ll never be the 51st state. We’re Canada; we’re proud to be Canadians. We’ll always fight for that.” Ettinger said civil society is similarly better to focus on convincing Americans to not impose damaging tariffs on Canada, instead of amping up anti-Trump rhetoric. “Canadians should worry first about what Canada’s actual national interests are,” he said. “We’re not going to out-trash talk Donald Trump, so don’t even bother trying and focus instead on the core stuff that really matters.” In response to Trump’s threats, the Trudeau Liberal government has unveiled a $1.3 billion spending package over six years to address Trump’s threats, which concern border security and the flow of illegal drugs into the United States. Canada’s ambassador to the U.S. Kirsten Hillman has repeatedly characterized Trump’s comments as gentle ribbing between two close countries. Foreign Affairs Minister Mélanie Joly said on Dec. 13 that she has quipped to Republican senators that they could join Canada as the eleventh province. Greenland’s head of government, Múte Bourup Egede, suggested that Trump’s latest calls to purchase the territory from Denmark would be as meaningless as those made in his first term. “Greenland is ours. We are not for sale and will never be for sale,” he said in a statement. “We must not lose our years-long fight for freedom.” Panama President José Raúl Mulino has also rebuffed Trump’s musing about taking over the Panama Canal. “Every square metre of the canal belongs to Panama and will continue to,” he said in a video, to which Trump fired back on his social media site, “We’ll see about that!”

In today's digital era, social media has become a powerful platform for individuals to express themselves, connect with others, and shape cultural trends. One phenomenon that has gained immense popularity in recent years is the rise of edgy influencers - individuals who push boundaries, challenge norms, and captivate audiences with their bold and unconventional content.

Title: What Does Bringing Up "Moderate Easing" Again After 14 Years Signify?Business combination closed November 13, 2024 Raised $10 million of gross proceeds in connection with the business combination Agreements are in place with Yorkville for up to a $50 million standby equity purchase agreement, to raise an additional $2 million in debt financing and the sale of up to 500,000 shares of common stock pursuant to forward purchase agreement Financing will support advancement of Abpro’s pipeline of its next-generation antibody therapies for cancer, ophthalmology, and infectious diseases WOBURN, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) (“Abpro”), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies, celebrated the closing of its business combination with Atlantic Coastal Acquisition Corp II (“ACAB”), a special purpose acquisition company, with a Nasdaq bell ringing ceremony. Abpro also celebrated the consummation of a PIPE offering raising $7 million in gross proceeds and a $2.76 million convertible note financing with YA II PN, LTD (“Yorkville”) to cover expenses in connection with the closing of the business combination. As previously announced, Abpro also has entered into a Standby Equity Purchase Agreement with Yorkville (the “SEPA”) pursuant to which Abpro has the right, but not the obligation, to issue up to $50 million in shares of its common stock to Yorkville upon registration of such shares, provided that no balance is outstanding on any promissory note to Yorkville (currently $3 million dollars outstanding). Among other restrictions and conditions set forth in the SEPA, the number of shares Abpro may request may not exceed the average of the daily traded amount of its shares of common stock during the five consecutive trading days preceding such request, and shall not cause Yorkville’s ownership to exceed 4.99% of the then outstanding common stock of Abpro, and the maximum amount of shares issued under the SEPA cannot exceed 19.99% of the outstanding common stock of Abpro without prior shareholder approval. Upon registration of the shares subject to the SEPA, Abpro has the right to receive financing for an additional $2 million. As previously announced, Abpro also has entered into a forward purchase agreement for the sale of up to 500,000 shares of common stock. Abpro believes that the various financings should significantly improve Abpro’s financial flexibility as it advances the development of its pipeline of its next-generation antibody therapies. “Becoming a public company represents a major milestone in our journey to provide solutions for patients with difficult-to-treat oncology and ophthalmology indications,” said Ian Chan, CEO and co-founder of Abpro. “The funds are expected to help accelerate the advancement of our pipeline to clinical trials. The financing will also provide the foundation for ongoing development of novel immunotherapies and next-generation antibody treatments in our pipeline with the aim of improving the lives of patients in need.” Abpro is advancing its pipeline of next-generation antibody therapies for HER2+ breast, gastric, and colorectal cancers, non-HER2+ gastric and liver cancer, wet age-related macular degeneration (AMD) and diabetic macular edema (DME), and infectious diseases. These next-generation antibodies are developed using Abpro's proprietary DiversImmune® platform, which creates antibody therapies against traditionally difficult targets. Abpro has partnered with Celltrion , a leading South Korean pharmaceutical company, in an exclusive global collaboration to further advance ABP 102, a T-cell engager, which is being developed for the treatment of HER2+ breast, gastric, and pancreatic cancers. Soo Young Lee, Senior Vice President and Head of the New Drug Division of Celltrion Inc. and a member of Abpro's Board of Directors, remarked, “Abpro’s ABP 102 drug candidate has shown preclinical data indicating the potential for better efficacy and less toxicity. We look forward to working closely with Abpro to advance ABP 102 into clinical trials.” Tony Eisenberg, who serves as a Director of Abpro, and had served as Chief Strategy Officer of ACAB prior to the business combination, added, “It’s an honor to be part of Abpro and the groundbreaking work they are doing. The Atlantic Coastal team is excited to have successfully completed this business combination with Abpro and to work with the Abpro management team to execute their long-term operational and strategic objectives as they develop next-generation antibody therapies with the potential to save lives and generate real return for investors.” Abpro’s Chairperson, Miles Suk, stated, "As the chairperson of the board, I am honored to guide Abpro through this landmark achievement. This listing marks a new chapter of growth and opportunity, and we remain committed to delivering sustainable value to our shareholders." About Abpro Abpro’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro is advancing a pipeline of next-generation antibody therapies, for HER2+ breast, gastric, and colorectal cancers, non-HER2+ gastric and liver cancer, wet age-related macular degeneration (AMD) and diabetic macular edema (DME), and infectious diseases. These antibodies are developed using Abpro's proprietary DiversImmune® platform. Abpro has partnered with Celltrion, which is a leading South Korean biotechnology company, ranked top 25 in the world by market capitalization, in an exclusive collaboration to further advance ABP 102, a T-cell engager, which is being developed for the treatment of HER2+ breast, gastric, and pancreatic cancer. Abpro is located in Woburn, Massachusetts. For more information, please visit www.abpro.com . Forward Looking Statements This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “aim,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including general economic, financial, legal, political and business conditions and changes in domestic and foreign markets; Abpro’s ability to raise additional capital; the outcome of judicial proceedings to which Abpro or its subsidiaries is, or may become a party; failure to realize the anticipated benefits of the Business Combination, including difficulty in, or costs associated with, integrating the businesses of ACAB and Abpro; risks related to the rollout of Abpro’s business and the cost and timing of expected business milestones; the effects of competition on Abpro’s future business; and those factors discussed in Abpro’s public filings under the heading “Risk Factors,” and other documents of Abpro filed, or to be filed, with the SEC. You should carefully consider the foregoing factors and the other risks and uncertainties that will be described in the “Risk Factors” section of Abpro’s public filings and other documents to be filed by Abpro from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward- looking statements, and while Abpro may elect to update these forward-looking statements at some point in the future, they assume no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law. Abpro does not give any assurance that Abpro will achieve its expectations. Actual results, performance or achievements may differ materially, and potentially adversely, from any projections and forward-looking statements and the assumptions on which those forward-looking statements are based. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance as projected financial information and other information are based on estimates and assumptions that are inherently subject to various significant risks, uncertainties and other factors, many of which are beyond our control.